TRDA
Entrada Therapeutics IncKey Statistics
About Entrada Therapeutics Inc
Entrada Therapeutics Inc. (TRDA) is a pioneering biotechnology firm focused on creating transformative therapies for severe diseases characterized by considerable unmet medical needs. Leveraging its proprietary Therapeutics for RNA Delivery (TRADA) platform, the company aims to tackle RNA and protein dysfunctions associated with various conditions, including muscular dystrophies and genetic disorders. With a robust clinical pipeline and a commitment to scientific excellence, Entrada is strategically positioned for impactful advancements in patient care. Backed by a seasoned management team, the company is set to make notable contributions to the biopharmaceutical landscape through its innovative therapeutic approaches.
Fundamentals
| Revenue (TTM) | $5.74M |
| Gross Profit (TTM) | $-135.81M |
| EBITDA | $-172.56M |
| Operating Margin | -4835.00% |
| Return on Equity | -48.30% |
| Return on Assets | -26.80% |
| Revenue/Share (TTM) | $0.14 |
| Book Value | $8.50 |
| Price-to-Book | 0.94 |
| Price-to-Sales (TTM) | 44.38 |
| EV/Revenue | 39.05 |
| EV/EBITDA | 1.58 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -95.70% |
| Shares Outstanding | $38.82M |
| Float | $19.47M |
| % Insiders | 12.31% |
| % Institutions | 78.42% |
Historical Volatility
Volatility is currently expanding